Vaxart (STU:NB11) Marketable Securities : €33.05 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Vaxart Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vaxart's Marketable Securities for the quarter that ended in Sep. 2024 was €33.05 Mil.

Vaxart's annual Marketable Securities increased from Dec. 2021 (€20.13 Mil) to Dec. 2022 (€46.92 Mil) but then declined from Dec. 2022 (€46.92 Mil) to Dec. 2023 (€4.55 Mil).

Vaxart Marketable Securities Historical Data

The historical data trend for Vaxart's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Marketable Securities Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

20.13

46.92

4.55

Vaxart Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Marketable Securities	Get a 7-Day Free Trial															18.55	4.55	9.14	17.94	33.05

Vaxart Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Vaxart (STU:NB11) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vaxart Marketable Securities Related Terms

Thank you for viewing the detailed overview of Vaxart's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

VXRT:USA VXRT:Mexico NB11:Germany

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Headlines

No Headlines